Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05268029 · ClinicalTrials.gov registry record
Making HD Voices Heard
A clinical trial, sponsored by Huntington Study Group.
- Completed
- Registry status
- 698
- Enrollment target
NCT05268029: Completed study, sponsored by Huntington Study Group.
NCT05268029 is a clinical trial that has completed, run by Huntington Study Group. The registered enrollment target is 698 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05268029 has completed, sponsored by Huntington Study Group.
- COMPLETED
- Registry status
- 698 participants
- Enrollment target
Study Summary
The Pilot Study, Making HD Voices Heard, will ask people living with HD to report what they experience and how they function.
Primary Outcome
Ability to successfully consent and enroll at least 200 manifest HD participants (independent or with help of assistants) within three months as measured by the number of help line calls or emails received requesting technical or clinical support.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 698 participants |
| Start Date | 2022-03-23 |
| Est. Completion | 2023-10-11 |
What the finished NCT05268029 record still lists
NCT05268029 is an observational study that tracks outcomes without assigning an intervention. The registered 698 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05268029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05268029 about?
NCT05268029 is a clinical study titled "Making HD Voices Heard". The Pilot Study, Making HD Voices Heard, will ask people living with HD to report what they experience and how they function.
What is the current status of trial NCT05268029?
This trial is currently completed. The enrollment target is 698 participants. The study started on 2022-03-23. Estimated completion is 2023-10-11.
Who is sponsoring clinical trial NCT05268029?
This trial is sponsored by Huntington Study Group, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03136094 · 698 participants · NA
Suicide in Urban Natives: Detection and Networks to Combat Events
- NCT04928846 · 698 participants · Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- NCT05943535 · 698 participants · Phase 3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- NCT07187115 · 699 participants · NA
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI